American Journal of Pharmacogenomics

, Volume 4, Issue 5, pp 331–341 | Cite as

Polymorphisms in Genes Involved in the Corticosteroid Response and the Outcome of Childhood Acute Lymphoblastic Leukemia

  • Isabelle Fleury
  • Melanie Primeau
  • Agnes Doreau
  • Irina Costea
  • Albert Moghrabi
  • Daniel Sinnett
  • Maja Krajinovic
Original Research Article



Considerable variability in sensitivity to corticosteroids (CS) has been observed among individuals with regard to both the natural and synthetic compounds. The role of genetic polymorphisms in modulating CS function, and hence in disease susceptibility, has been extensively analyzed. Their impact on therapeutic response still remains to be explored. The role of cytochrome P450 (CYP) 3A4 in corticosteroid metabolism, and that of the glucocorticoid receptor (NR3C1) in regulation of responsive genes, renders CYP3A4 and NR3C1 polymorphisms as potential candidates for pharmacogenetic analysis.


The aim of the study was to analyze the role of these polymorphisms in the outcome of a disease treated with CS drugs.


Towards this aim we analyzed the CYP3A4–290A/G substitution and three NR3C1 polymorphisms (200G/A, 1220A/G and BclI RFLP) in 222 children with acute lymphoblastic leukemia (ALL) whose treatment protocols, among other components, contained corticosteroid drugs.


The analysis of survival probabilities in relation to the indicated genotypes showed only an association between homozygosity for allele G of the NR3C1 BclI RFLP polymorphism and overall survival (univariate and multivariate hazard ratio [HR] 2.7, 95% confidence interval [CI] 1.0, 7.6 and 5.2, 95% CI 1.4, 18.9, respectively). The association reflects a correlation with disease progression and prognosis, and may vary depending on risk of relapse.


A reduction in survival probability in children with ALL was associated with homozygosity for G allele of the NR3C1 BclI RFLP polymorphism, particularly in certain patient subgroups. Further analysis is required to replicate this finding and to understand the mechanism underlying the observed association.



We are indebted to all the patients and their parents who consented to participate in this study. We are grateful to our colleagues Damian Labuda for discussion and biological material, Mark Bernstein for facilitating access to clinical data, and Alan Lovell for critical reading of the manuscript.

Isabelle Fleury has a studentship, and Maja Krajinovic and Daniel Sinnett scholarships from the Fonds de la recherche en santé du Québec. The Cancer Research Society, Inc. and Centre de Recherche, Hôpital Ste-Justine supported this study.

The authors have no conflicts of interest directly relevant to the content of this study.


  1. 1.
    Bray PJ, Cotton RG. Variations of the human glucocorticoid receptor gene (NR3C1): pathological and in vitro mutations and polymorphisms. Hum Mutat 2003; 21: 557–68PubMedCrossRefGoogle Scholar
  2. 2.
    Iida S, Nakamura Y, Fujii H, et al. A patient with hypocortisolism and Cushing’s syndrome-like manifestations: cortisol hyperreactive syndrome. J Clin Endocrinol Metab 1990; 70: 729–37PubMedCrossRefGoogle Scholar
  3. 3.
    Lamberts SW, Koper JW, Biemond P, et al. Cortisol receptor resistance: the variability of its clinical presentation and response to treatment. J Clin Endocrinol Metab 1992; 74: 313–21PubMedCrossRefGoogle Scholar
  4. 4.
    Pui CH. Acute lymphoblastic leukemia in children. Curr Opin Oncol 2000; 12: 3–12PubMedCrossRefGoogle Scholar
  5. 5.
    Krynetski EY, Evans WE. Genetic polymorphism of thiopurine S-methyltransferase: molecular mechanisms and clinical importance. Pharmacology 2000; 61: 136–46PubMedCrossRefGoogle Scholar
  6. 6.
    Krajinovic M, Labuda D, Sinnett D. Pharmacogenetics of childhood acute lymphoblastic leukemia. Curr Pharmacogenetics 2003; 1: 87–100CrossRefGoogle Scholar
  7. 7.
    Holleman A, Cheok MH, den Boer ML, et al. Gene expression patterns in drug-resistant ALL cells and response to treatment. N Engl J Med 2004; 351: 533–42PubMedCrossRefGoogle Scholar
  8. 8.
    Gaynon PS, Carrel AL. Glucocorticosteroid therapy in childhood acute lymphoblastic leukemia. Adv Exp Med Biol 1999; 457: 593–605PubMedCrossRefGoogle Scholar
  9. 9.
    Kofler R. The molecular basis of glucocorticoid-induced apoptosis of lymphoblastic leukemia cells. Histochem Cell Biol 2000; 114: 1–7PubMedGoogle Scholar
  10. 10.
    Siebe H, Baude G, Lichtenstein I, et al. Metabolism of dexamethasone: sites and activity in mammalian tissues. Ren Physiol Biochem 1993; 16: 79–88PubMedGoogle Scholar
  11. 11.
    Chabner BA, Allegra CA, Curt GA, et al. Antineoplastic agents. In: Hardman JG, Gilman AG, Limbird LE, editors. The pharmacological basis of therapeutics. New York: McGraw-Hill, 1996Google Scholar
  12. 12.
    Hurwitz CA, Silverman LB, Schorin MA, et al. Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer 2000; 88: 1964–9PubMedCrossRefGoogle Scholar
  13. 13.
    Schimmer BP, Parker KL. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs. In: Hardman JG, Limbird LE, Gilman AG, editors. The pharmacological basis of therapeutics. New York: McGraw-Hill, 1996: 1649–78Google Scholar
  14. 14.
    Feiner EI, Thompson MT, Ratliff AF, et al. Time course of recovery of adrenal function in children treated for leukemia. J Pediatr 2000; 137: 21–4CrossRefGoogle Scholar
  15. 15.
    Waber DP, Carpentieri SC, Klar N, et al. Cognitive sequelae in children treated for acute lymphoblastic leukemia with dexamethasone or prednisone. J Pediatr Hematol Oncol 2000; 22: 206–13PubMedCrossRefGoogle Scholar
  16. 16.
    Mattano LA, Sather HN, Trigg ME, et al. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children’s Cancer Group. J Clin Oncol 2000; 18: 3262–72PubMedGoogle Scholar
  17. 17.
    Greenstein S, Ghias K, Krett NL, et al. Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies. Clin Cancer Res 2002; 8: 1681–94PubMedGoogle Scholar
  18. 18.
    Arai K, Chrousos GP. Hormone-nuclear receptor interactions in health and disease: glucocorticoid resistance. Baillieres Clin Endocrinol Metab 1994; 8: 317–31PubMedCrossRefGoogle Scholar
  19. 19.
    Panarelli M, Fraser R. The glucocorticoid receptor and hypertension. Endocr Res 1994; 20: 101–16PubMedCrossRefGoogle Scholar
  20. 20.
    de Lange P, Segeren CM, Koper JW, et al. Expression in hematological malignancies of a glucocorticoid receptor splice variant that augments glucocorticoid receptor-mediated effects in transfected cells. Cancer Res 2001; 61: 3937–41PubMedGoogle Scholar
  21. 21.
    Krett NL, Pillay S, Moalli PA, et al. A variant glucocorticoid receptor messenger RNA is expressed in multiple myeloma patients. Cancer Res 1995; 55: 2727–9PubMedGoogle Scholar
  22. 22.
    Longui CA, Vottero A, Adamson PC, et al. Low glucocorticoid receptor alpha/beta ratio in T-cell lymphoblastic leukemia. Horm Metab Res 2000; 32: 401–6PubMedCrossRefGoogle Scholar
  23. 23.
    Fleury I, Beaulieu P, Primeau M, et al. Characterization of the BclI polymorphism in the glucocorticoid receptor gene. Clin Chem 2003; 49: 1528–31PubMedCrossRefGoogle Scholar
  24. 24.
    Rosmond R, Chagnon YC, Holm G, et al. A glucocorticoid receptor gene marker is associated with abdominal obesity, leptin, and dysregulation of the hypothalamic-pituitary-adrenal axis. Obes Res 2000; 8: 211–8PubMedCrossRefGoogle Scholar
  25. 25.
    Panarelli M, Holloway CD, Fraser R, et al. Glucocorticoid receptor polymorphism, skin vasoconstriction, and other metabolic intermediate phenotypes in normal human subjects. J Clin Endocrinol Metab 1998; 83: 1846–52PubMedCrossRefGoogle Scholar
  26. 26.
    Ukkola O, Perusse L, Chagnon YC, et al. Interactions among the glucocorticoid receptor, lipoprotein lipase and adrenergic receptor genes and abdominal fat in the Quebec Family Study. Int J Obes Relat Metab Disord 2001; 25: 1332–9PubMedCrossRefGoogle Scholar
  27. 27.
    Buemann B, Vohl MC, Chagnon M, et al. Abdominal visceral fat is associated with a BclI restriction fragment length polymorphism at the glucocorticoid receptor gene locus. Obes Res 1997; 5: 186–92PubMedGoogle Scholar
  28. 28.
    Weaver JU, Hitman GA, Kopelman PG. An association between a BclI restriction fragment length polymorphism of the glucocorticoid receptor locus and hyperinsulinaemia in obese women. J Mol Endocrinol 1992; 9: 295–300PubMedCrossRefGoogle Scholar
  29. 29.
    Koper JW, Stolk RP, de Lange P, et al. Lack of association between five polymorphisms in the human glucocorticoid receptor gene and glucocorticoid resistance. Hum Genet 1997; 99: 663–8PubMedCrossRefGoogle Scholar
  30. 30.
    van Rossum EF, Koper JW, Huizenga NA, et al. A polymorphism in the glucocorticoid receptor gene, which decreases sensitivity to glucocorticoids in vivo, is associated with low insulin and cholesterol levels. Diabetes 2002; 51: 3128–34PubMedCrossRefGoogle Scholar
  31. 31.
    DeRijk RH, Schaaf M, de Kloet ER. Glucocorticoid receptor variants: clinical implications. J Steroid Biochem Mol Biol 2002; 81: 103–22PubMedCrossRefGoogle Scholar
  32. 32.
    Huizenga NA, Koper JW, De Lange P, et al. A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. J Clin Endocrinol Metab 1998; 83: 144–51PubMedCrossRefGoogle Scholar
  33. 33.
    Abel SM, Maggs JL, Back DJ, et al. Cortisol metabolism by human liver in vitro: I. Metabolite identification and inter-individual variability. J Steroid Biochem Mol Biol 1992; 43: 713–9PubMedCrossRefGoogle Scholar
  34. 34.
    Tomlinson ES, Lewis DF, Maggs JL, et al. In vitro metabolism of dexamethasone (DEX) in human liver and kidney: the involvement of CYP3A4 and CYP17 (17,20 LYASE) and molecular modelling studies. Biochem Pharmacol 1997; 54: 605–11PubMedCrossRefGoogle Scholar
  35. 35.
    Garg V, Jusko WJ. Simultaneous analysis of prednisone, prednisolone and their major hydroxylated metabolites in urine by high-performance liquid chromatography. J Chromatogr 1991; 567: 39–47PubMedCrossRefGoogle Scholar
  36. 36.
    Gentile DM, Tomlinson ES, Maggs JL, et al. Dexamethasone metabolism by human liver in vitro: metabolite identification and inhibition of 6-hydroxylation. J Pharmacol Exp Ther 1996; 277: 105–12PubMedGoogle Scholar
  37. 37.
    Rebbeck TR, Jaffe JM, Walker AH, et al. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998; 90: 1225–9PubMedCrossRefGoogle Scholar
  38. 38.
    Amirimani B, Walker AH, Weber BL, et al. RESPONSE: re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1999; 91: 1588–90PubMedCrossRefGoogle Scholar
  39. 39.
    Felix CA, Walker AH, Lange BJ, et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci U S A 1998; 95: 13176–81PubMedCrossRefGoogle Scholar
  40. 40.
    Silverman LB, Gelber RD, Kimball Dalton V, et al. Improved outcomes for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001; 97: 1211–8PubMedCrossRefGoogle Scholar
  41. 41.
    Laverdiere C, Chiasson S, Costea I, et al. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 2002; 100: 3832–4PubMedCrossRefGoogle Scholar
  42. 42.
    Labuda D, Krajinovic M, Richer C, et al. Rapid detection of CYP1A1, CYP2D6, and NAT variants by multiplex polymerase chain reaction and allele-specific oligonucleotide assay. Anal Biochem 1999; 275: 84–92PubMedCrossRefGoogle Scholar
  43. 43.
    Bourgeois S, Labuda D. Dynamic allele-specific oligonucleotide hybridization on solid support (DASO). Anal Biochem 2004; 324: 309–11PubMedCrossRefGoogle Scholar
  44. 44.
    Krajinovic M, Labuda D, Sinnett D. Glutathione S-transferase P1 genetic polymorphisms and susceptibility to childhood acute lymphoblastic leukaemia. Pharmacogenetics 2002; 12: 655–8PubMedCrossRefGoogle Scholar
  45. 45.
    Stevens A, Ray DW, Zeggini E, et al. Glucocorticoid sensitivity is determined by a specific glucocorticoid receptor haplotype. J Clin Endocrinol Metab 2004; 89: 892–7PubMedCrossRefGoogle Scholar
  46. 46.
    Hongo T, Yamada S, Yajima S, et al. Biological characteristics and prognostic value of in vitro three-drug resistance to prednisolone, L-asparaginase, and vincristine in childhood acute lymphoblastic leukemia. Int J Hematol 1999; 70: 268–77PubMedGoogle Scholar
  47. 47.
    Kaspers GJ, Veerman AJ, Pieters R, et al. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood 1997; 90: 2723–9PubMedGoogle Scholar
  48. 48.
    Bailey S, Hall AG, Pearson AD, et al. Glucocorticoid resistance and the AP-1 transcription factor in leukaemia. Adv Exp Med Biol 1999; 457: 615–9PubMedCrossRefGoogle Scholar
  49. 49.
    Huizenga NA, Koper JW, de Lange P, et al. Interperson variability but intraperson stability of baseline plasma cortisol concentrations, and its relation to feedback sensitivity of the hypothalamo-pituitary-adrenal axis to a low dose of dexamethasone in elderly individuals. J Clin Endocrinol Metab 1998; 83: 47–54PubMedCrossRefGoogle Scholar
  50. 50.
    Lamberts SW, Huizenga AT, de Lange P, et al. Clinical aspects of glucocorticoid sensitivity. Steroids 1996; 61: 157–60PubMedCrossRefGoogle Scholar
  51. 51.
    Pascussi JM, Gerbal-Chaloin S, Drocourt L, et al. The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochim Biophys Acta 2003; 1619: 243–53PubMedCrossRefGoogle Scholar
  52. 52.
    El-Sankary W, Plant NJ, Gibson GG, et al. Regulation of the CYP3A4 gene by hydrocortisone and xenobiotics: role of the glucocorticoid and pregnane X receptors. Drug Metab Dispos 2000; 28: 493–6PubMedGoogle Scholar
  53. 53.
    Aplenc R, Glatfelter W, Han P, et al. CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia. Br J Haematol 2003; 122: 240–4PubMedCrossRefGoogle Scholar
  54. 54.
    Lin RC, Wang WY, Morris BJ. High penetrance, overweight, and glucocorticoid receptor variant: case-control study. BMJ 1999; 319: 1337–8PubMedCrossRefGoogle Scholar
  55. 55.
    Lin RC, Wang XL, Morris BJ. Association of coronary artery disease with glucocorticoid receptor N363S variant. Hypertension 2003; 41: 404–7PubMedCrossRefGoogle Scholar
  56. 56.
    Dobson MG, Redfern CP, Unwin N, et al. The N363S polymorphism of the glucocorticoid receptor: potential contribution to central obesity in men and lack of association with other risk factors for coronary heart disease and diabetes mellitus. J Clin Endocrinol Metab 2001; 86: 2270–4PubMedCrossRefGoogle Scholar
  57. 57.
    van Rossum EF, Koper JW, van den Beld AW, et al. Identification of the BclI polymorphism in the glucocorticoid receptor gene: association with sensitivity to glucocorticoids in vivo and body mass index. Clin Endocrinol (Oxf) 2003; 59: 585–92CrossRefGoogle Scholar
  58. 58.
    Di Blasio AM, van Rossum EF, Maestrini S, et al. The relation between two polymorphisms in the glucocorticoid receptor gene and body mass index, blood pressure and cholesterol in obese patients. Clin Endocrinol (Oxf) 2003; 59: 68–74CrossRefGoogle Scholar
  59. 59.
    Griffin TC, Shuster JJ, Buchanan GR, et al. Slow disappearance of peripheral blood blasts is an adverse prognostic factor in childhood T cell acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Leukemia 2000; 14: 792–5PubMedCrossRefGoogle Scholar
  60. 60.
    Schwartz CL, Thompson EB, Gelber RD, et al. Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemia. J Clin Oncol 2001; 19: 1040–6PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  • Isabelle Fleury
    • 1
  • Melanie Primeau
    • 1
  • Agnes Doreau
    • 1
  • Irina Costea
    • 1
  • Albert Moghrabi
    • 1
    • 2
  • Daniel Sinnett
    • 1
    • 2
  • Maja Krajinovic
    • 1
    • 2
  1. 1.Research CenterSainte-Justine Hospital, Centre Hospitalier Universitaire Mère-EnfantMontrealCanada
  2. 2.Department of PediatricsUniversity of MontrealMontrealCanada

Personalised recommendations